Browsing by Subject "CD28 superagonist"
Now showing items 1-1 of 1
-
CD28 Superagonistic Activation of T Cells Induces a Tumor Cell-Like Metabolic Program
( Mary Ann Liebert Inc. , 2019 , Article)CD28 superagonist (CD28SA), a therapeutic immunomodulatory monoclonal antibody triggered rapid and exaggerated activation of CD4+ effector memory T cells (TEMs) in humans with unwanted serious adverse effects. It is well ...